Thus, the resultant decrease of Abeta CSF (in function of age) closely mimics the situation in AD patients and provides an efficacy biomarker in preclinical studies directed to evaluate Abeta-modulating drugs. The gene discussed is APP; the disease is Alzheimer disease.